Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD38 | P28907 | 11/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | RPS6KB1 | P23443 | 7/20 | 0.40 |
| ▸ | AURKA | O14965 | 5/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12280689 | 0.86 | CD38 (0.41) | CD38CYP3A4RPS6KB1AURKAJAK2 | |
| SCHEMBL12280127 | 0.81 | MAPK8 (0.42) | CD38CYP3A4RPS6KB1AURKAJAK2 | |
| SCHEMBL2483074 | 0.80 | CD38 (0.57) | CD38CYP3A4RPS6KB1AURKAJAK2 | |
| SCHEMBL2474877 | 0.77 | CD38 (0.54) | CD38CYP3A4RPS6KB1AURKAJAK2 | |
| SCHEMBL2478248 | 0.76 | AURKA (0.54) | CD38CYP3A4RPS6KB1AURKAJAK2 | |
| SCHEMBL2477334 | 0.75 | AURKA (0.51) | CD38CYP3A4RPS6KB1AURKAJAK2 | |
| SCHEMBL2476571 | 0.75 | CD38 (0.54) | CD38CYP3A4RPS6KB1AURKAJAK2 | |
| SCHEMBL12280679 | 0.75 | JAK3 (0.46) | CD38CYP3A4RPS6KB1AURKAJAK2 | |
| SCHEMBL2342817 | 0.74 | SYK (0.42) | CD38CYP3A4RPS6KB1AURKAJAK2 | |
| SCHEMBL12454564 | 0.74 | CD38 (0.44) | CD38CYP3A4RPS6KB1AURKAJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230467-A1 | 4,6-DIAMINONICOTINAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230467-A1 | 4,6-DIAMINONICOTINAMIDE COMPOUND | JAK3, JAK2, JAK1 | CD38 1118/4885CYP3A4 3849/4885RPS6KB1 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.